HRP20250591T1 - 5‑[[4‑[2‑[5‑(1‑hidroksietil)piridin‑2‑il]etoksi]fenil]metil]‑1,3‑tiazolidin‑2,4‑dion i njegove soli, namijenjen upotrebi u liječenju mitohondrijskih bolesti - Google Patents
5‑[[4‑[2‑[5‑(1‑hidroksietil)piridin‑2‑il]etoksi]fenil]metil]‑1,3‑tiazolidin‑2,4‑dion i njegove soli, namijenjen upotrebi u liječenju mitohondrijskih bolestiInfo
- Publication number
- HRP20250591T1 HRP20250591T1 HRP20250591TT HRP20250591T HRP20250591T1 HR P20250591 T1 HRP20250591 T1 HR P20250591T1 HR P20250591T T HRP20250591T T HR P20250591TT HR P20250591 T HRP20250591 T HR P20250591T HR P20250591 T1 HRP20250591 T1 HR P20250591T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- thiazolidine
- dione
- pyridin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382397 | 2018-06-06 | ||
| PCT/IB2019/054696 WO2019234664A1 (en) | 2018-06-06 | 2019-06-06 | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases |
| EP19742480.7A EP3801515B1 (en) | 2018-06-06 | 2019-06-06 | 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20250591T1 true HRP20250591T1 (hr) | 2025-07-04 |
Family
ID=62716008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20250591TT HRP20250591T1 (hr) | 2018-06-06 | 2019-06-06 | 5‑[[4‑[2‑[5‑(1‑hidroksietil)piridin‑2‑il]etoksi]fenil]metil]‑1,3‑tiazolidin‑2,4‑dion i njegove soli, namijenjen upotrebi u liječenju mitohondrijskih bolesti |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11957670B2 (https=) |
| EP (2) | EP3801515B1 (https=) |
| JP (1) | JP7376934B2 (https=) |
| DK (1) | DK3801515T3 (https=) |
| ES (1) | ES3028538T3 (https=) |
| FI (1) | FI3801515T3 (https=) |
| HR (1) | HRP20250591T1 (https=) |
| HU (1) | HUE071482T2 (https=) |
| LT (1) | LT3801515T (https=) |
| PL (1) | PL3801515T3 (https=) |
| PT (1) | PT3801515T (https=) |
| SI (1) | SI3801515T1 (https=) |
| WO (1) | WO2019234664A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| JP7734917B2 (ja) | 2019-01-28 | 2025-09-08 | ミトコンドリア エモーション， インク． | トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法 |
| AU2019427489B2 (en) | 2019-01-28 | 2025-03-13 | Mitochondria Emotion, Inc. | Mitofusin activators and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201391017A1 (ru) | 2011-01-10 | 2014-04-30 | Зинфандел Фармасьютикалз, Инк. | Способы и готовые лекарственные формы для лечения болезни альцгеймера |
| WO2014210389A1 (en) | 2013-06-26 | 2014-12-31 | Rett Syndrome Research Trust | Rett syndrome and treatments therefore |
| EP3094328B1 (en) | 2014-01-15 | 2020-08-19 | Poxel SA | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| EA202091120A3 (ru) | 2014-04-02 | 2020-12-30 | Минорикс Терапьютикс С.Л. | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы |
| JP6791154B2 (ja) | 2015-09-30 | 2020-11-25 | 株式会社ニコン | 露光装置、フラットパネルディスプレイの製造方法、及びデバイス製造方法 |
| WO2017083739A1 (en) | 2015-11-13 | 2017-05-18 | The Trustees Of Columbia University In The City Of New York | A method for predicting a subject's response to valproic acid therapy |
| CN106202285A (zh) | 2016-06-30 | 2016-12-07 | 北京百度网讯科技有限公司 | 搜索结果展示方法和装置 |
| JP7040798B2 (ja) | 2016-12-01 | 2022-03-23 | ミノリックス セラピューティクス エセ．エレ． | 非アルコール性脂肪性肝疾患を処置するための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオン |
| ES2926580T3 (es) | 2016-12-23 | 2022-10-27 | Minoryx Therapeutics S L | Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil]etoxi]fenil]metil]-2,4-tiazolidindiona y sales de la misma |
| CN112823004A (zh) | 2018-06-06 | 2021-05-18 | 米尼奥尔克斯治疗有限公司 | 5-[[4-[2-[5-乙酰基吡啶-2-基]乙氧基]苄基]-1,3-噻唑烷-2,4-二酮及其盐的用途 |
| CN112512524A (zh) | 2018-06-06 | 2021-03-16 | 米尼奥尔克斯治疗有限公司 | 给予治疗有效量的5-[[4-[2-[5-(1-羟基乙基)吡啶-2-基]乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮的方法 |
-
2019
- 2019-06-06 EP EP19742480.7A patent/EP3801515B1/en active Active
- 2019-06-06 LT LTEPPCT/IB2019/054696T patent/LT3801515T/lt unknown
- 2019-06-06 US US16/972,375 patent/US11957670B2/en active Active
- 2019-06-06 PT PT197424807T patent/PT3801515T/pt unknown
- 2019-06-06 SI SI201930937T patent/SI3801515T1/sl unknown
- 2019-06-06 ES ES19742480T patent/ES3028538T3/es active Active
- 2019-06-06 EP EP25162244.5A patent/EP4545142A3/en active Pending
- 2019-06-06 HU HUE19742480A patent/HUE071482T2/hu unknown
- 2019-06-06 FI FIEP19742480.7T patent/FI3801515T3/fi active
- 2019-06-06 PL PL19742480.7T patent/PL3801515T3/pl unknown
- 2019-06-06 WO PCT/IB2019/054696 patent/WO2019234664A1/en not_active Ceased
- 2019-06-06 DK DK19742480.7T patent/DK3801515T3/da active
- 2019-06-06 JP JP2020567815A patent/JP7376934B2/ja active Active
- 2019-06-06 HR HRP20250591TT patent/HRP20250591T1/hr unknown
-
2024
- 2024-04-12 US US18/633,922 patent/US20250064791A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3801515T3 (pl) | 2025-07-14 |
| DK3801515T3 (da) | 2025-04-28 |
| PT3801515T (pt) | 2025-06-11 |
| EP3801515B1 (en) | 2025-04-09 |
| US20250064791A1 (en) | 2025-02-27 |
| SI3801515T1 (sl) | 2025-07-31 |
| ES3028538T3 (en) | 2025-06-19 |
| JP7376934B2 (ja) | 2023-11-09 |
| EP3801515A1 (en) | 2021-04-14 |
| LT3801515T (lt) | 2025-06-10 |
| JP2021527049A (ja) | 2021-10-11 |
| HUE071482T2 (hu) | 2025-08-28 |
| US20210228559A1 (en) | 2021-07-29 |
| EP4545142A3 (en) | 2025-06-11 |
| WO2019234664A1 (en) | 2019-12-12 |
| EP4545142A2 (en) | 2025-04-30 |
| FI3801515T3 (fi) | 2025-05-27 |
| US11957670B2 (en) | 2024-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20250591T1 (hr) | 5‑[[4‑[2‑[5‑(1‑hidroksietil)piridin‑2‑il]etoksi]fenil]metil]‑1,3‑tiazolidin‑2,4‑dion i njegove soli, namijenjen upotrebi u liječenju mitohondrijskih bolesti | |
| HRP20170352T1 (hr) | Spojevi bis(fluroalkil)-1,4-benzodiazepinona kao notch inhibitori | |
| SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
| HRP20160678T1 (hr) | Derivati 2-(1,2,3-triazol-2-il)benzamida i 3-(1,2,3-triazol-2-il)pikolinamida kao antagonisti receptora oreksina | |
| JP2006077019A5 (https=) | ||
| HRP20210576T1 (hr) | 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion, namijenjen liječenju nealkoholne masne bolesti jetre | |
| HRP20210447T1 (hr) | Piridinski spoj | |
| JP2020516671A5 (https=) | ||
| JP2013531031A5 (https=) | ||
| HRP20130738T1 (hr) | Postupak lijeäśenja ili profilakse | |
| HRP20140593T1 (hr) | Derivati 1,3-disupstituiranih imidazolidin-2-ona kao cyp 17-inhibitori | |
| JP2013527243A5 (https=) | ||
| JP2019500387A5 (https=) | ||
| NZ592748A (en) | 2-Amino-(oxadiazol-3-yl)-benzofuran derivatives and their use as S1P receptor modulators | |
| JP2009532464A5 (https=) | ||
| JP2016505619A5 (https=) | ||
| JP2014528464A5 (https=) | ||
| JP2017537940A5 (https=) | ||
| JP2013510825A5 (https=) | ||
| JP2013539789A5 (https=) | ||
| RU2015121043A (ru) | Производные фенилэтилпиридина в качестве ингибиторов PDE-4 | |
| JP2014500265A5 (https=) | ||
| JP2014509647A5 (https=) | ||
| JP2017505293A5 (https=) | ||
| HRP20161797T1 (hr) | Spojevi 1,3-oksazolidina ili 1,3-oksazinana kao antagonisti receptora oreksina |